{"id":456785,"date":"2021-03-12T08:33:33","date_gmt":"2021-03-12T13:33:33","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=456785"},"modified":"2021-03-12T08:33:33","modified_gmt":"2021-03-12T13:33:33","slug":"anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\/","title":{"rendered":"Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">Technology invented and developed at Cleveland Clinic<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">SAN JOSE, Calif.<\/span>, <span class=\"xn-chron\">March 12, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3095056-1&amp;h=553085348&amp;u=http%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc.\" rel=\"nofollow noopener noreferrer\">Anixa Biosciences, Inc.<\/a> (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the European Patent Office has issued and published the first European patent for its novel ovarian cancer vaccine technology.\u00a0 This technology was invented and developed at Cleveland Clinic and Anixa is the worldwide licensee.\u00a0\u00a0\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/602982\/ITUS_Corporation_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/602982\/ITUS_Corporation_Logo.jpg\" title=\"Anixa Biosciences, Inc. (PRNewsfoto\/Anixa Biosciences, Inc.)\" alt=\"Anixa Biosciences, Inc. (PRNewsfoto\/Anixa Biosciences, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>The patent is titled, &#8220;Ovarian Cancer Vaccines,&#8221; and the inventors are Drs. <span class=\"xn-person\">Vincent K. Tuohy<\/span>, <span class=\"xn-person\">Suparna Mazumder<\/span>, and <span class=\"xn-person\">Justin M. Johnson<\/span>, all of Cleveland Clinic.<\/p>\n<p>Dr. <span class=\"xn-person\">Amit Kumar<\/span>, President and CEO of Anixa Biosciences, stated, &#8220;We are pleased that the European Patent Office (EPO) has issued this patent.\u00a0 This ovarian cancer vaccine has the potential to eliminate one of the deadliest malignancies in women.\u00a0 Ovarian cancer is often diagnosed after it has reached Stage 3 or 4, and when it is difficult to effectively treat.\u00a0 Five-year survival statistics for ovarian cancer are poor, so if this vaccine is able to eliminate the onset of ovarian cancer, the impact for women and for our healthcare system will be tremendous.&#8221;<\/p>\n<p>&#8220;The ovarian cancer vaccine targets a protein (the Extracellular Domain of the Anti-Mullerian Hormone Receptor 2, AMHR2-ED) that is expressed only in the ovaries and only in pre-menopausal women.\u00a0 After menopause, the target protein disappears and is only seen again when ovarian cancer cells arise.\u00a0 Our vaccine targets the AMHR2-ED and trains the immune system to destroy these cancer cells as they arise,&#8221; said Dr. <span class=\"xn-person\">Vincent Tuohy<\/span> of the Department of Inflammation and Immunity at Cleveland Clinic&#8217;s Lerner Research Institute.\u00a0 &#8220;We are looking forward to our continued alliance with Anixa Biosciences to further develop this technology.&#8221; <\/p>\n<p>\n        <b>About Anixa Biosciences, Inc.<br \/><\/b>Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. \u00a0Anixa&#8217;s therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. \u00a0The company&#8217;s vaccine portfolio includes a vaccine to prevent breast cancer, and specifically triple negative breast cancer (TNBC), the most deadly form of the disease, and a vaccine to prevent ovarian cancer. \u00a0These vaccine technologies focus on immunizing against specific proteins that have been found to be expressed in certain forms of cancer. \u00a0Anixa continually examines emerging technologies in complementary fields for further development and commercialization. \u00a0Additional information is available at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3095056-1&amp;h=2255274220&amp;u=http%3A%2F%2Fwww.anixa.com%2F&amp;a=www.anixa.com\" rel=\"nofollow noopener noreferrer\">www.anixa.com<\/a>.<\/p>\n<p>\n        <b><br \/>\n          <i>Forward-Looking Statements:<\/i><br \/>\n        <\/b>\u00a0 Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. \u00a0Forward-looking statements are not statements of historical facts, but rather reflect Anixa&#8217;s current expectations concerning future events and results. \u00a0We generally use the words &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;likely,&#8221; &#8220;will&#8221; and similar expressions to identify forward-looking statements. \u00a0Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. \u00a0These risks, uncertainties and factors include, but are not limited to, those factors set forth in &#8220;Item 1A &#8211; Risk Factors&#8221; and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. \u00a0We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. \u00a0You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.<\/p>\n<p>Investor contact:<br \/><span class=\"xn-person\">Mike Catelani<\/span><br \/><a target=\"_blank\" href=\"mailto:mcatelani@anixa.com\" rel=\"nofollow noopener noreferrer\">mcatelani@anixa.com<\/a><br \/>408-708-9808<\/p>\n<p>Media contact:<br \/><span class=\"xn-person\">Sherry Ash<\/span><br \/><a target=\"_blank\" href=\"mailto:anixapress@gmail.com\" rel=\"nofollow noopener noreferrer\">anixapress@gmail.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA07641&amp;sd=2021-03-12\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology-301246332.html\">http:\/\/www.prnewswire.com\/news-releases\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology-301246332.html<\/a><\/p>\n<p>SOURCE  Anixa Biosciences, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA07641&amp;Transmission_Id=202103120830PR_NEWS_USPR_____LA07641&amp;DateId=20210312\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Technology invented and developed at Cleveland Clinic PR Newswire SAN JOSE, Calif., March 12, 2021 \/PRNewswire\/ &#8212;\u00a0Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the European Patent Office has issued and published the first European patent for its novel ovarian cancer vaccine technology.\u00a0 This technology was invented and developed at Cleveland Clinic and Anixa is the worldwide licensee.\u00a0\u00a0\u00a0 The patent is titled, &#8220;Ovarian Cancer Vaccines,&#8221; and the inventors are Drs. Vincent K. Tuohy, Suparna Mazumder, and Justin M. Johnson, all of Cleveland Clinic. Dr. Amit Kumar, President and CEO of Anixa Biosciences, stated, &#8220;We are pleased that the European Patent Office (EPO) has issued this patent.\u00a0 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-456785","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Technology invented and developed at Cleveland Clinic PR Newswire SAN JOSE, Calif., March 12, 2021 \/PRNewswire\/ &#8212;\u00a0Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the European Patent Office has issued and published the first European patent for its novel ovarian cancer vaccine technology.\u00a0 This technology was invented and developed at Cleveland Clinic and Anixa is the worldwide licensee.\u00a0\u00a0\u00a0 The patent is titled, &#8220;Ovarian Cancer Vaccines,&#8221; and the inventors are Drs. Vincent K. Tuohy, Suparna Mazumder, and Justin M. Johnson, all of Cleveland Clinic. Dr. Amit Kumar, President and CEO of Anixa Biosciences, stated, &#8220;We are pleased that the European Patent Office (EPO) has issued this patent.\u00a0 &hellip; Continue reading &quot;Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-12T13:33:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/602982\/ITUS_Corporation_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology\",\"datePublished\":\"2021-03-12T13:33:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\\\/\"},\"wordCount\":670,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/602982\\\/ITUS_Corporation_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\\\/\",\"name\":\"Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/602982\\\/ITUS_Corporation_Logo.jpg\",\"datePublished\":\"2021-03-12T13:33:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/602982\\\/ITUS_Corporation_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/602982\\\/ITUS_Corporation_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\/","og_locale":"en_US","og_type":"article","og_title":"Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology - Market Newsdesk","og_description":"Technology invented and developed at Cleveland Clinic PR Newswire SAN JOSE, Calif., March 12, 2021 \/PRNewswire\/ &#8212;\u00a0Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the European Patent Office has issued and published the first European patent for its novel ovarian cancer vaccine technology.\u00a0 This technology was invented and developed at Cleveland Clinic and Anixa is the worldwide licensee.\u00a0\u00a0\u00a0 The patent is titled, &#8220;Ovarian Cancer Vaccines,&#8221; and the inventors are Drs. Vincent K. Tuohy, Suparna Mazumder, and Justin M. Johnson, all of Cleveland Clinic. Dr. Amit Kumar, President and CEO of Anixa Biosciences, stated, &#8220;We are pleased that the European Patent Office (EPO) has issued this patent.\u00a0 &hellip; Continue reading \"Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-12T13:33:33+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/602982\/ITUS_Corporation_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology","datePublished":"2021-03-12T13:33:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\/"},"wordCount":670,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/602982\/ITUS_Corporation_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\/","name":"Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/602982\/ITUS_Corporation_Logo.jpg","datePublished":"2021-03-12T13:33:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/602982\/ITUS_Corporation_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/602982\/ITUS_Corporation_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/456785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=456785"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/456785\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=456785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=456785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=456785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}